Integragen (XPAR:ALINT) Ending Cash Position: €0.00 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALINT Integragen XPAR:ALINT
33 GF Score
Price €0.19
GF Value €0.42
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Integragen Ending Cash Position?

Integragen XPAR:ALINT -4.62% 33 Ending Cash Position is €0.00 Mil as of Jun. 2025. GuruFocus rates XPAR:ALINT with a GF Score™ of 33/100 and a GF Value™ of €0.42 (Possible Value Trap). The stock has 4 warning signs investors should review.

Integragen's Ending Cash Position for the quarter that ended in Jun. 2025 was €0.00 Mil.

Integragen Ending Cash Position Related Terms

Integragen Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Integragen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integragen Ending Cash Position Chart

Integragen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Integragen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALINT
33GF Score
Integragen XPAR:ALINT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integragen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Integragen's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Integragen's Ending Cash Position for the quarter that ended in Jun. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.00 Mil mean?
Integragen (XPAR:ALINT) has a Ending Cash Position of €0.00 Mil as of Jun. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Integragen and its competitors.
Is Integragen's Ending Cash Position too high?
Integragen's current Ending Cash Position is €0.00 Mil. Overall, Integragen has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integragen's Ending Cash Position compare to VRTX and REGN?
Integragen's Ending Cash Position of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Integragen and its competitors. Integragen's current Ending Cash Position is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integragen stock overvalued right now?
Based on GuruFocus' analysis, Integragen (XPAR:ALINT) is currently considered Possible Value Trap. The stock's GF Value™ is €0.42, compared to a current price of €0.19 — trading 55.7% below its estimated fair value. The current Ending Cash Position is €0.00 Mil. Integragen's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Integragen (XPAR:ALINT), the current Ending Cash Position is €0.00 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integragen (XPAR:ALINT) Overvalued in 2026?

Based on GuruFocus' analysis, Integragen stock appears to be undervalued. The current stock price of €0.19 is trading 55.7% below its estimated GF Value™ of €0.42. GuruFocus considers Integragen to be Possible Value Trap.

Key valuation signals for XPAR:ALINT:

  • Ending Cash Position: €0.00 Mil
  • GF Value™: €0.42 vs. price of €0.19 (55.7% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integragen Business Description

Other Exchanges 7N8:Germany
Address Genopole Campus 1 - Genavenir, 85 rue Henri Desbrueres, Evry, FRA, 91000
Integragen is engaged in the development of genetic biomarkers. It offers genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, as well as genomic research tools and solutions to microbiologic researchers.
33GF Score

Get the complete analysis for XPAR:ALINT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€0.42
GF Value